OncoDaily Pulse

Aug 29, 2025, 00:57

Çağatay Arslan: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register via the link.

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Çağatay Arslan

Prof. Çağatay Arslan is a Professor and Medical Oncologist at Medical Park İzmir Hospital in Turkey. He is recognized for his expertise in renal cell carcinoma, with a special focus on variant histologies such as chromophobe RCC.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Prof. Arslan will present on “Chromophobe RCC: Diagnosis and Treatment” during the Variant Histologies in RCC session. His presentation will explore:

Diagnostic criteria and challenges specific to chromophobe renal cell carcinoma.
Current and emerging therapeutic options tailored for this rare RCC subtype.
Insights into the molecular and clinical features that influence management decisions.
Strategies to optimize patient care and improve outcomes for individuals with chromophobe RCC.

With his clinical expertise and research focus, Prof. Arslan emphasizes a comprehensive and individualized approach to managing chromophobe RCC, aiming to advance treatment paradigms and enhance patient outcomes across Europe and beyond.

Global Voices in Renal Oncology (VIRO) 2025